Your session is about to expire
← Back to Search
Other
Atomoxetine + Oxybutynin for Sleep Apnea
Phase 1 & 2
Recruiting
Led By Scott A Sands, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Suspected or diagnosed OSA
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 days
Awards & highlights
Study Summary
This trial finds that people with sleep apnea who have certain pathophysiological traits respond better to Atomoxetine-plus-oxybutynin therapy.
Who is the study for?
This trial is for people with suspected or diagnosed obstructive sleep apnea who have recent drug-induced sleep endoscopy results. It's not for those with uncontrolled medical conditions, other major respiratory disorders, using certain medications like hypnotics or SSRIs, pregnant or nursing women, and individuals with a range of specific health issues such as severe hypertension, heart failure, liver/kidney disease.Check my eligibility
What is being tested?
The study tests whether Atomoxetine-plus-oxybutynin therapy (AtoOxy) effectively reduces the severity of obstructive sleep apnea in patients. Researchers will identify which patients benefit most based on traits measured during initial sleep studies.See study design
What are the potential side effects?
Potential side effects from Atomoxetine and Oxybutynin may include allergic reactions like angioedema or urticaria, mood changes including mania or depression in young adults under 24 years old, constipation, difficulty urinating due to urinary retention, seizures in those predisposed to them.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have or might have sleep apnea.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Apnea
Secondary outcome measures
Arousal Index
Hypoxia
Side effects data
From 2008 Phase 4 trial • 57 Patients • NCT0022401618%
Infection
18%
Headache
15%
Urinary tract infection
15%
Fever
13%
Pharyngitis
13%
Rash
13%
Vomiting
10%
Pain
10%
Constipation
8%
Pain abdominal
8%
Pruritis
8%
Rhinitis
8%
Diarrhea
8%
Pain back
5%
VP shunt malfunction
5%
Skin ulcer
3%
Gastritis
3%
Knee wound dehiscence
3%
Worsening dehydration
3%
Tethered cord
100%
80%
60%
40%
20%
0%
Study treatment Arm
Oxybutynin TDS
Oral Oxybutynin
Trial Design
2Treatment groups
Experimental Treatment
Group I: AtoOxy Predicted RespondersExperimental Treatment2 Interventions
Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
Group II: AtoOxy Predicted NonrespondersExperimental Treatment2 Interventions
Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atomoxetine
2010
Completed Phase 4
~431790
Oxybutynin
2015
Completed Phase 4
~2720
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Obstructive Sleep Apnea (OSA) include pharmacological agents like Atomoxetine and Oxybutynin. Atomoxetine, a selective norepinephrine reuptake inhibitor, increases norepinephrine levels, which can enhance upper airway muscle tone and reduce airway collapse during sleep.
Oxybutynin, an anticholinergic agent, reduces muscle spasms and airway resistance through its antimuscarinic effects. These mechanisms are crucial for OSA patients as they offer a pharmacological means to reduce OSA severity by improving airway patency, providing an alternative or complement to traditional treatments like CPAP.
The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double blind, placebo controlled, randomized, cross-over trial.The pharmacotherapeutic management of obstructive sleep apnea.The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double blind, placebo controlled, randomized, cross-over trial.The pharmacotherapeutic management of obstructive sleep apnea.The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,622 Previous Clinical Trials
11,468,722 Total Patients Enrolled
Scott A Sands, PhDPrincipal InvestigatorBrigham and Women's Hospital
6 Previous Clinical Trials
243 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a sleep disorder like restless legs, sleep attacks, or unusual behaviors during sleep.I don't have allergies to atomoxetine or oxybutynin, heart, kidney, liver issues, or certain mental health conditions.I am not taking medications that affect my breathing.I am currently taking SNRIs/SSRIs or anticholinergic medications.I do not have any uncontrolled medical conditions.I do not have major neurological disorders, heart failure, or other unstable conditions.I have recent results from a sleep study done under sedation.I have a lung condition that is not sleep-related and causes low oxygen levels.I am currently taking sleep medications.I am currently taking the medication being studied.Developing high blood pressure on the last day of my study medication won't stop my participation.I have or might have sleep apnea.
Research Study Groups:
This trial has the following groups:- Group 1: AtoOxy Predicted Responders
- Group 2: AtoOxy Predicted Nonresponders
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger